VP-01 is a small molecule commercialized by Vicore Pharma, with a leading Phase I program in Pulmonary Arterial Hypertension. According to Globaldata, it is involved in 12 clinical trials, of which 8 were completed, 1 is ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of VP-01’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for VP-01 is expected to reach an annual total of $95 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
VP-01 is under development for the treatment of idiopathic pulmonary fibrosis and pulmonary arterial hypertension (PAH). It is administered through oral and intravenous route. The drug candidate is a small non-peptide. It is highly selective for the angiotensin II receptor type-2 (AT2) receptor. The drug is based on a receptor targeting technology which includes molecules with agonistic action to the AT2 receptor. It was under development for the treatment of coronavirus disease 2019 (COVID-19).
Vicore Pharma Overview
Vicore Pharma formerly Pharmacore, a subsidiary of Vicore Pharma Holding AB, operates as a biotechnology company focused on the development of orphan drugs for the treatment of fibrotic diseases. Its lead product candidate C21 that stimulates the AT2 receptors is used for the treatment of idiopathic pulmonary fibrosis (IPF). Its portfolio includes small molecules with potential indications which are used in various therapeutic indications such as anti-inflammation, neuro protection, neuro regeneration, and cardiovascular diseases. The company seeks to work in collaboration with pharmaceutical companies to accelerate the development and licensing opportunities for its pipeline products. Vicore Pharma is headquartered in Molndal, Sweden.
For a complete picture of VP-01’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.